Clinical lung cancer
-
Clinical lung cancer · Mar 2011
ReviewSummary of presentations from the 46th annual meeting of the American Society Of Clinical Oncology (2010): focus on developmental therapeutics related to lung cancer.
A number of novel agents are currently being tested in clinical trials in patients with cancer. Results from early-phase trials, often in unselected groups of patients with a wide variety of cancer types, were reported at the 46th annual meeting of the American Society of Clinical Oncology (ASCO). We report on selected studies from the developmental therapeutics track (abstracts 2500-2613 and 3000-3108) that may be of interest to the thoracic oncology community.
-
The history of small-cell lung cancer (SCLC) is one of the more fascinating stories of medicine, a story of hope and disappointment that characterizes it as 1 of the most elusive cancers. Its history can be divided into 3 intervals. ⋯ The second interval, from the 1960s-1980s, introduced advances in staging and treatment of SCLC and the advent of chemotherapy and radiation therapy (RT) as the primary forms of therapy. The final interval covers the past 25 years, which is considered a dormant period, although there are some shimmers of hope from the emergence of several new active drugs that are currently undergoing clinical trials.